Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, ...

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer has entered into an exclusive global licensing agreement with 3SBio to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF pathways. The therapy is ...